Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2020-09-25 Earnings Release
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is explicitly titled "Lysogene annonce ses résultats semestriels 2020 et fait le point sur ses activités" (Lysogene announces its 2020 half-year results and provides an update on its activities). It contains detailed financial tables comparing H1 2020 results to H1 2019, including revenue, operating expenses, and net income, all based on IFRS accounts for the period ending June 30, 2020. This content structure—a press release summarizing period-end financial figures and operational progress for a period shorter than a year—is the definition of an Interim/Quarterly Report (IR). Although it is presented as a press release, the core content is the comprehensive financial reporting for the half-year period, making 'IR' the most accurate classification over 'ER' (Earnings Release, which is usually just highlights) or 'RPA' (Report Publication Announcement, as this document contains the results, not just an announcement that results are coming). H2 2020
2020-09-25 French
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "Lysogene : point d'avancement à la fin du premier semestre 2020" (Lysogene: progress update at the end of the first half of 2020) and is explicitly labeled as a "Communiqué de presse" (Press Release). It provides key financial highlights (cash position as of June 30, 2020, revenue recognition) and operational updates (FDA letter regarding clinical trial LYS-SAF302). This format, summarizing period-end results and key events in a brief press release format, strongly aligns with an Earnings Release (ER), which typically contains the initial announcement of periodical financial results and highlights, rather than the comprehensive Interim Report (IR) or the full Annual Report (10-K). Since it covers the first half (H1) of the year, it is a periodic financial update. H1 2020
2020-07-24 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is explicitly titled "Press Release" and provides a "First Half 2020 Business Update." It details key financial metrics (cash position, revenues) and operational milestones (FDA letter regarding LYS-SAF302 trial) for the first six months of the year. This content structure—a summary of recent performance and operational status released via press release—is characteristic of an Earnings Release (ER), which provides initial highlights for a reporting period shorter than a year. It is not the comprehensive Interim/Quarterly Report (IR) itself, but the initial announcement of the period's results. H2 2020
2020-07-24 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "**Press Release**" and announces a specific corporate event: a research collaboration between Lysogene and the Weizmann Institute of Science regarding gene therapy approaches. This type of announcement, detailing strategic business developments, partnerships, or scientific milestones, is typically classified as a general regulatory announcement or press release that doesn't fit into the highly specific categories like 10-K, ER, or DIV. Since it is a formal announcement that doesn't fit the definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS, the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2020-07-01 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) dated July 1, 2020, announcing a research partnership between Lysogene and the Weizmann Institute of Science regarding gene therapy approaches. This type of announcement, detailing a specific business development (partnership, clinical trial update, etc.) released to the public via press release, is characteristic of an Earnings Release (ER) if it contained financial highlights, or more generally, a Regulatory Filing (RNS) if it's a general corporate announcement not fitting other specific categories. Since it is a press release announcing a strategic development (partnership) and not a full financial report (10-K, IR), nor a transcript (CT), nor a specific management/board change (MANG), it fits best as a general corporate announcement. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standard corporate news releases that aren't explicitly covered elsewhere, although 'ER' often covers press releases announcing results. Since this is a partnership announcement, RNS is the most appropriate fallback for a significant corporate event announcement that isn't a formal financial report or earnings summary.
2020-07-01 French
Inside Information / Other news releases
AGM Information Classification · 1% confidence The document is explicitly titled 'LYSOGENE releases the results from June 26, 2020 ordinary annual and extraordinary general meeting' and details that shareholders approved all proposed resolutions, including financial statements and compensation policy. This content directly relates to the outcomes and proceedings of an Annual General Meeting (AGM). Although it announces the results, the core content is the summary of the meeting's decisions, making AGM-R (AGM Information) the most appropriate classification, rather than just RPA or ER. The document confirms the meeting took place and lists the key approvals.
2020-06-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.